Pfizer revealed on Wednesday that it gave its first dose to a patient participating in its phase 2/3 clinical trial examining the efficacy of an orally administered drug that is designed to combat COVID-19.
CEO Albert Bourla on Wednesday night wrote on Twitter that “success against COVID19 will likely require both vaccines [and] treatments” and said the pharmaceutical giant started a “Phase 2/3 study of our oral antiviral candidate—specifically designed to combat SARS-CoV-2—in non-hospitalized, low-risk adults.”
